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CLUSION: The association of cost-effectiveness dimensions may
provide us with an estimated measure of EAPs’ ability to resolve
issues, between centres and UBAs. In general, a direct associa-
tion holds between the efﬁciency index and higher effectiveness
of interventions. The data must be assessed cautiously with ref-
erence to the external validity of the study.
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AN ASSESMENT OF TWO IRANIAN SOCIAL SECURITY
ORGANIZATION HOSPITALS PERFORMANCE BASED ON THE
EFQM MODEL
Maleki MR, Izadi A
Iran Medical University (IUMS),Tehran, Iran
OBJECTIVES: During recent years, due to the importance of
health services, health care managers attend to increase of hos-
pital services quality. The European Foundation for Quality
Management (EFQM) Excellence Model was performed as a
competition framework to recognition of achievement to orga-
nizational quality, performance excellence and growth of orga-
nizational knowledge about quality and performance excellence.
METHODS: The method of this research is descriptive and
cross-sectional. This research had been done in Alborz and
panzdah khordad varamin hospitals. Data gathering tool was the
EFQM questionnaire that had been completed during group
working sessions, interview with leaders of the hospitals and
referring to necessitous units. Research data had been gathered
according to nine criteria of in the hospitals. RESULTS: Find-
ings had been showed that Alborz hospital has had the higher
score in leadership criterion (46.1%), policy and strategy
(50.6%) processes (61%). Panzdah khordad hospital has had the
higher score in people (47.39%), partnership and resources
(49.5%), customer results (46.1%), people results (39%), society
results (40.6%) and key performance results (56.25%). Totally,
the ﬁnding shows that Panzdah khordad hospital had been
higher score 471.56 and then Alborz hospital with 439.55
scores. CONCLUSION: Assessment of hospital performance
based on The EFQM Model is the ﬁrst empirical experience in
Iranian hospitals. The ﬁndings have showed that European
Organizational Excellence Model is very applicable in health
care. Benchmark and supervision to hospital performance will
be possible by using the model especially in management atten-
tion and follow up to hospital. The assessment gave an overall
picture of the organization and was a ﬁrst step to introduce a
systemic view and a common view.
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OBJECTIVE: To compare the cost-effectiveness of etanercept +
methotrexate (MTX) and inﬂiximab + MTX for the treatment
of severe rheumatoid arthritis (SRA) patients in Brazil.
METHODS: An analytic-decision model for projecting the
annual costs of treating SRA in Brazil was developed consider-
ing local procedures and a payer perspective. The clinical effec-
tiveness was based on American College of Rheumatology
criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70).
For inﬂiximab a 70 kg patient was considered. The data used in
the analysis were obtained from public sources: Ofﬁcial Price
List; products labels; Ofﬁcial Physicians Fees List and local arti-
cles published in indexed journals. To ensure similarities in
patient proﬁle, the ACR20, 50, 70 responses from: Weinblatt,
1999 (etanercept) and Maini, 1999 (inﬂiximab) were chosen for
the effectiveness measures. RESULTS: For the annual treatment
cost, Inﬂiximab 10 mg/kg every 4 weeks (INF.10/4 = R$255,935)
was the most expensive therapy followed by inﬂiximab 10 mg/kg
every 8 weeks (INF.10/8 = R$148,284); etanercept 50 mg every
week (ETA = R$88,247); inﬂiximab 3 mg/kg every 4 weeks
(INF.3/4 = R$80,104); and inﬂiximab 3 mg/kg every 8 weeks
(INF.3/8 = R$47,809). However, assuming INF.3/4 as the average
dosing schedule, ETA shows lower average cost-effectiveness
(C/E) ratios for ACR20: (ETA) R$124,291 vs. (INF.3/4)
R$160,209; ACR50: (ETA) R$226,273 vs. (INF.3/4)
R$276,222; and ACR70: (ETA) R$588,310 vs. (INF.3/4)
R$728,222. Etanercept offers favorable C/E ratios in 3 out of 4
scenarios for each ACR response. This was conﬁrmed by a one-
way sensitivity analysis applying a 10% variance in either prices
or in ACR responses. The incremental cost-effectiveness ratio
ranged from R$38,772 to R$203,522 for ETA relative to
INF.3/4. CONCLUSIONS: Findings suggest etanercept as a com-
petitive cost-effectiveness therapy. Etanercept performs better
especially when it is compared with the intermediate/high
dosages per kilo of inﬂiximab.
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OBJECTIVE: To assess the cost-effectiveness of a single intra-
venous dose of zoledronic acid 5 mg (ZOL) compared to a daily
regimen of oral risedronate 30 mg (RIS) over 2 months in the
long-term (2-year) management of Paget’s disease of the bone
(PDB) in Germany. METHODS: A model-based incremental
cost-effectiveness analysis was conducted over four half-year
cycles. Clinical efﬁcacy was reﬂected in four health states:
response, non-response, relapse, no-relapse. Response was
deﬁned as normalization of the serum alkaline phosphatase
(SAP) value after 6 months. Relapse was deﬁned as an increase
in SAP of at least 50% from the value at 6 months and at least
1.25 times the upper normal limit. Retreatment was assumed in
case of non-response or relapse. Efﬁcacy data were obtained
from two 6-month randomized clinical trials which compared
ZOL with RIS in patients with PDB. Relapse data were obtained
from the extended observation phase of the trial, in which SAP
was measured at 6-monthly intervals to determine whether
patients were still in response. The analysis was conducted from
the German payers’ perspective. Only direct health care costs
such as those for physician visits, SAP measurement and drug
administration were considered. Cost data were derived from
published sources for the year 2006. Costs and effects in the
second year were discounted by 5%. A probabilistic sensitivity
analysis (PSA) was performed to investigate the robustness of the
results. RESULTS: Due to more responders and longer remis-
sion, treatment with ZOL resulted in an incremental of 6.2
months in response and a cost saving of 243 € over 2 years com-
pared to RIS. The results of the PSA indicated that ZOL was
more effective and cost-saving with 100% certainty. CONCLU-
SION: ZOL presents a dominant treatment option in the long-
term management of PDB indicating superior effectiveness at a
lower cost.
